INTRODUCTION
Community-acquired pneumonia (CAP) is a common and frequent entity, encountered by all medical specialities. The history of CAP follows the history of humanity.
In 1881, Pasteur and Sternberg [1, 2] independently described a microorganism, referred to as Pneumococcus by Fraenkel [3] , because it caused pulmonary disease. Two decades later, Osler [4] identified the clinical entity of pneumonia as the 'Captain of the men of death''. The introduction of serum therapy, and particularly vaccines and antibiotics, had a major impact in the treatment and prevention of pneumonia during the first half of the 20th century. However, in the last 50-60 years, no novel treatment has been introduced. Simultaneously, there are new pathogens (e.g. severe acute respiratory-syndrome coronavirus and middle east respiratory-syndrome coronavirus) and multidrug-resistant pathogens are becoming more common. As a result, pneumonia remains a major public health problem, with enormous morbidity and mortality [5] , being globally the second cause of years of life lost, only behind ischemic heart disease.
In 1993, the American Thoracic Society (ATS) published the first guidelines on CAP [6] . This groundbreaking document had major clinical impact in patient management. Despite many advances, some challenges persist. These include the difficulty in making the initial clinical diagnosis, risk stratification, the empirical choice of antibiotics, the relative scarcity of novel antibiotics and the importance of knowing local microbiological susceptibility patterns.
It is expected that the next Infectious Disease Society of America (IDSA)/ATS guidelines actualization due in 2018 will clarify some of these challenges. Some changes are already anticipated [7 & ]. Although most research on CAP is based on inpatients, the lack of research in the outpatient setting justifies the need to adapt the main conclusions to the outpatient reality.
EPIDEMIOLOGY
Several limitations contribute to the difficulty in establishing the incidence of CAP. These include the different methodologies used for diagnosis, the studied population and the fact that most cases are treated as outpatients where chest X-ray (CXR) confirmation is not sought [8] . It is estimated as an annual incidence of 5-11 cases per 1000 adults [9] . Incidence is greater in winter, in the elderly, in men and in the presence of multiple risk factors such as alcohol and/or tobacco consumption, chronic pulmonary disease, renal failure and malnutrition [10 & ]. The rate of hospital admissions for CAP varies between countries, reflecting different population and health organization characteristics, with values that range between 1.1 and 4.0 per 1000 inhabitants [11] . Most CAP cases are managed in the community and, in Europe, estimates suggest that 50-80% of cases will be managed as outpatients [8] . The annual incidence of hospitalized CAP in the United States has recently been estimated as 24.8 per 10 000 adults [12] , slightly inferior to the value calculated in 1991 of 26.7 per 10 000 adults [13] . This is contrary to several European countries, where an increased rate of CAP admission has been documented in the UK [11] , Germany [14] and Portugal [15] .
Globally, lower respiratory tract infections (LRTIs), including CAP, were the fourth leading cause of death in 2015 [16] . In developed countries, CAP is the leading cause of death by infectious disease [7 & ], and it was the eighth cause of death in the United States in 2014 [17] .
The last decade the United States has seen a decrease in CAP mortality to figures lower than 20 deaths per 100,000 population, a number probably related to the routine immunization of children with the conjugated pneumococcal vaccine and public reporting of CAP process of care, mortality and readmission rates [7 & ].
CAUSE
Although more than 100 microorganisms can cause CAP, a limited and small number is responsible for most cases. Nowadays, the use of molecular diagnostic techniques can attain a microbiological diagnosis in 75% of cases [18] ; however, in the usual hospital setting, a microbiological result is achieved in only 10-20% of cases [19] .
In a review of 46 European studies [20] in the outpatient setting, there was microbiological isolation in half the patients. Pneumococcus was the most common organism accounting for 38% of isolates. The pneumococcal incidence is higher in countries with lower use of pneumococcal vaccines and higher tobacco use [21] . In some countries, a new Streptococcus pneumoniae urinary antigen test by immunofluorescence is available with promising results when compared with the usual colorimetric method [22] .
In a Norwegian study [23] , held between 2008 and 2010 with 267 inpatients, the cause was determined in 63% of cases. The most common pathogens were S. pneumoniae (30%), influenza (15%) and rhinovirus (12%). Viral-bacterial codetections were established in approximately one third of patients. In a US study from 2012 with 2320 inpatients, cause was established in 38% of patients. The most commonly identified pathogens were rhinovirus, with 9% incidence, influenza virus in 6% and pneumococcus in 5% [12] .
Despite the frequent identification of viruses, their role as colonizers, predisposing to secondary bacterial infection or as microorganisms responsible for pneumonia, is not totally established, particularly for noninfluenza viruses.
In the previously mentioned review [20] , atypical microorganisms were responsible for 30% of CAP cases in the outpatient setting. In a study done in four Dutch hospitals, atypical microorganisms were isolated in 20.7% of patients [24] . Factors associated with atypical agents were: CAP acquired in the nonrespiratory
KEY POINTS
The majority of patients with CAP are treated as outpatients; however, most of the research on CAP originates from inpatients.
The main challenges in the outpatient management of CAP persist. These include the initial clinical diagnosis, its risk stratification and the empirical choice of antibiotics.
Despite the growing acknowledgment of viral agents, all patients with CAP should receive antibiotic treatment. These should be adapted from current guidelines and must take into account local microbiological susceptibility patterns.
The worrying problem of antibiotic resistance increases the need for stewardship programmes that maintain current antibiotics, safeguard future ones and reinforce prevention.
season, age under 60 years, male sex and the absence of chronic obstructive pulmonary disease.
CAP due to Legionella species is more frequent in specific geographic locations and tends to occur after specific exposures. Since 2014, several legionella outbreaks have been reported in New York City [25] , New Zealand [26] , Japan [27] and the world's second largest, with 430 cases, in Portugal [28] . This outbreak has the first documented case of probable person-to-person transmission of Legionnaires' disease [29 & ].
DIAGNOSIS AND RISK STRATIFICATION
Diagnosis of pneumonia is based on the presence of lower respiratory tract signs and symptoms, systemic manifestations and a new or progressive pulmonary infiltrate in CXR. Finally, there is the need of microbiologic documentation [9] . These criteria are far from ideal as they are highly sensitive but poorly specific [30] . The diagnosis is made more complicated and dubious in the community as it usually relies solely on clinical evaluation. To make matters worse, there are several conditions, infectious and noninfectious, which could mimic pneumonia.
The clinician dealing with a suspected pneumonia faces two possible scenarios; the availability of resources that aid diagnosis such as radiology, laboratory and microbiology, or clinical judgment alone when in a resource limited situation. In the first scenario, the clinician can tailor investigations according to severity. This will both support the diagnosis of pneumonia and its place of treatment. In addition, investigations allow the use of prediction scores such as Pneumonia Severity Index or CURB-65, which help in the decision-making process. The resource-limited setting is the usual one and carries a greater risk of uncertainty. With clinical evaluation only, or rarely, with the help of basic additional assessments, such as pulse oximetry or point-of-care clinical chemistry, the clinician needs to decide between community treatment or hospital referral.
There are clinical scoring systems, such as CRB-65, which can be useful in resource-limited settings. The CRB-65 score is a simplified version of CURB-65, but, unfortunately less extensively evaluated [31] . There are, however, data showing that it performs similarly to CURB-65 in the assessment of mortality risk [32] and in predicting ICU admission [33] .
The development of compact and easy-to-use devices has brought the possibility of assessment of several laboratory variables in point-of-care setting, namely C-reactive protein (CRP) and procalcitonin (PCT). There are two trials performed in primary care using a biomarker decision tree algorithm in patients with suspicion of LRTI [34] [35] [36] . In the PCT trial, the inclusion criterion was suspicion of a LRTI in which the attending physician was willing to give antibiotics. They found a significant reduction in antibiotic prescription without increase in the adverse events [34] . The CRP trial was a cluster randomized controlled trial assessing two interventions, CRP test and communication skills. It was found that CRP test per se significantly decreased antibiotic prescription (P ¼ 0.02) without adverse events.
Some new devices will probably become available soon, namely lung ultrasound (LUS) and low radiation computed tomography (CT). However, as with other radiologic technique, LUS has also interobserver variability and it is not within purview of expertise of most primary care physicians.
Some have proposed that with the widespread availability of modern generation low radiation CT, this could become almost a routine diagnostic investigation [7 & ]. However, this strategy could have several drawbacks. As CT has a higher sensitivity, it would identify minor infiltrates, of unknown cause, which would likely increase antibiotic prescription. Also, if CT became widely available, its interpretation would rest upon the attending physician as it now occurs with CXR. This could result in more investigations and workload in order to follow up incidental findings. Importantly, the current chest CT carries 350x the radiation of a CXR [37] and even the low radiation CT still has 75x more. These are important figures as it is a well established association between CT radiation exposure and the future risk of cancer [38] .
TREATMENT
Antibiotic treatment is recommended to all patients with CAP, including those treated in the community [6, 9, [39] [40] [41] . The principles of antibiotic management were subjected to a comprehensive review [42 & ]. Treatment success rests on prompt delivery of antibiotics, adapted to the likely causative organisms and severity. Treatment options should take into consideration local guidelines, up-to-date and adapted to the microorganism prevalence and susceptibility pattern (Table 1) [6, 39, 43, 44, 40, 41] .
The importance of antibiotic expedient delivery was validated again in an observational study from Catalonia involving 3364 inpatients. Patients who started antibiotic treatment in the community had lower incidence of septic shock and invasive mechanical ventilation [45] .
In the community, options vary between countries but usually include monotherapy with a blactam, macrolide or tetracycline. These choices exclude those with significant chronic conditions www.co-infectiousdiseases.comor those at risk for antibiotic resistance. Fluoroquinolones are frequently used, but from an antibiotic stewardship perspective, a narrower coverage is preferable, particularly in countries with higher tuberculosis prevalence [41] . In the United States, according with a retrospective analysis using MarketScan Commercial & Medicare Supplemental Databases, from 2011 to 2015, and involving 251 947 adult patients the most commonly prescribed antibiotics in the outpatient were macrolides (43.6%), fluoroquinolones (43%), b-lactam compounds (6.5%) and tetracyclines (5.5%) [46] .
In the UK [9] , the need to cover atypical microorganisms is not considered significant. However, both Mycoplasma pneumoniae and Chlamydia pneumoniae can cause severe CAP and adequate antibiotic, even in mild disease, can reduce morbidity and symptom duration [47] .
A recent Dutch study (CAP-START) compared treatment between a b-lactam or fluoroquinolone as monotherapy and a b-lactam and a macrolide in inpatients [48] . There was no significant difference in 90-day mortality between the three options. However, this study had several limitations. In 25% of patients, there was no radiographic confirmation of pneumonia, atypical organisms were identified in only 2% of patients, 39% of patients on the monotherapy b-lactam group had atypical coverage and 12% of patients on the b-lactam and macrolide did not receive a macrolide [7 & ,42 & ]. Antimicrobial resistance is a growing problem in the community. The current level of b-lactam pneumococcal resistance in the community is not generally associated with treatment failure when appropriate agents (e.g. amoxicillin, ceftriaxone and cefotaxime) and adequate doses are used [49] . However, the level of pneumococcal and mycoplasma macrolide resistance, which reaches 55-60% for azithromycin in China [40] , can limit the use of macrolides as monotherapy [50] . The development of new antibiotics is crucial and ideally soon new drugs will be available.
For outpatient, the most promising seem to be solithromycin, omadacycline and lefamulin (Table 2) . In December 2016, food and drug administration requested further safety investigations for solithromycin that might impact the future of this fourthgeneration macrolide.
REASSESSMENT
An effective clinical response to therapy in CAP is usually defined as clinical stabilization, including absence of fever, normalization of respiratory and heart rate, normal blood pressure and recovery of abnormal O 2 saturation [40] . Among outpatients, treatment failure is usually defined as the need for hospitalization or change in antibiotic therapy.
Although there are not much data assessing nonresponse in the outpatient setting, therapeutic failure seems to be unusual, ranging from 2.3 [51] to 7.5% [52] or 8% [53] and appeared to be mainly related to the patient's comorbidities and not to antibiotic selection or to the pneumonia itself.
Moreover, mortality is low, both in studies addressing patients with pneumonia discharged from the emergency department [51, 54] or assessed in the primary care setting, less than 2.5% [52] . This is in line with the original Pneumonia Patient Outcomes Research Team data [55] , in which mortality rate was below 3% for all three lower risk classes. Yet, a note of caution is needed as the mortality rate in the small group of patients who had late hospital admission was quite high [54] .
National Institute for Health and Care Excellence guidelines [44] recommend that explanation should be provided to patients with low-severity CAP, and when appropriate to their families, to seek further medical advice if their symptoms do not begin to improve in a short period or if they feel that their condition is deteriorating. This approach seems to be quite intuitive, although there are scarce data to support it. A clinical reevaluation, either in the clinic or by phone, may be a simple approach able to identify nonresponse.
Recommendations should be provided for the ambulatory-treated patient. Not only treatment failure increases the risk, it may also be associated with increased costs. In a large cohort (N ¼ 9446) in the United States, authors identified a 58% increase in costs when treatment failure occurred, with either antibiotic retreatment (89.4%) or hospitalization (10.6%) [56] . Authors were also able to relate treatment failure to a higher level of resistance to macrolides (!25%), especially in those later hospitalized (13.1 vs. 8%, P < 0.001) [56] .
PREVENTION
In 2015, after the publication of the CAPITA trial, there was a significant increase in recommendations for immunization in adults [57] . In the United States, the Advisory Committee on Immunization Practices recommends in all adults aged at least 65 years the 13-valent pneumococcal conjugate vaccine (PCV13) [58] and at least 1 year after the 23-valent pneumococcal polysaccharide vaccine (PPSV23) [59] . Despite their recommendations, the uptake of PCV13 in the United States is low among adults aged 65 and older. Using Medicare claims data, centers for disease control and prevention (CDC) researchers found that by 2016, 43% of beneficiaries had received at least one dose of PPSV23, 32% had one dose of PCV13 and 18% had received both. The highest vaccination cover was seen among patients who were older, white or had chronic medical conditions [60] . In other developed countries, pneumococcal vaccination is widely recommended. France now recommends the scheme PCV13->PPSV23 to all immunocompromised or immunocompetent adults at risk due to a predisposing condition for pneumococcal disease [61] .
Several studies [10 & ,62] investigated the association between CAP and lifestyle factors. The association leads to a bundle of lifestyle interventions that include smoking cessation, responsible alcohol consumption, dental hygiene, dietary advice to ensure good nutritional status, the avoidance of children with LRTI and vaccination against influenza and pneumococcus [62] .
CONCLUSION
Most CAP patients are treated in the community; however, most of the research comes from inpatients. Since the publication of CAP guidelines in 1993, the main challenges persist. These include the difficulty in establishing the initial diagnosis, its risk stratification, the empirical choice of antibiotics and the importance of local microbiological susceptibility patterns. New molecular biology methods have changed the etiologic perspective of CAP, particularly its viral contribution. LUS and biomarkers might aid diagnosis and severity stratification; however, further studies are needed. Antibiotic resistance is a growing problem that reinforces the importance of novel antibiotics and disease prevention.
